Extended-Release Niacin with Laropiprant

HPS2-THRIVE trial Among patients with atherosclerotic vascular disease, the addition of extended-release niacin–laropiprant to statin-based LDL cholesterol–lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events.   Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients — NEJM.

Sudden cardiac death

What is sudden cardiac death (SCD) ? Sudden cardiac death is defined as natural death from cardiac causes, heralded by abrupt loss of consciousness within 1 hour of the onset of an acute change in cardiovascular status. Related terms are sudden cardiac arrest and cardiovascular collapse. Sudden cardiac arrest means abrupt cessation of cardiac mechanical […]

Top 10 Cardiology articles of the week (07.07.14-13.07.14)

1.Comprehensive Analysis of Mortality Among Patients Undergoing TAVR: Results of the PARTNER Trial J Am Coll Cardiol. 2014;64(2):158-168 2. Glycosylated hemoglobin A1c as a marker predicting the severity of coronary artery disease and early outcome in patients with stable angina Lipids Health Dis. 2014; 13: 89 3.Association Between Intensification of Metformin Treatment With Insulin vs […]

Top 10 Cardiology articles of the week (30.6.14- 6.7.14)

1. Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy : The PREVAIL Trial. In this trial, LAA occlusion was noninferior to warfarin for ischemic stroke                                      prevention […]

%d bloggers like this: